


Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)
Approved for use on 10/25/2002 OMB 0531-0011
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known JUN 14 2001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/712,481
				Filing Date	November 16 2000
				First Named Inventor	Watanabe and Choi
				Group Art Unit	1623
				Examiner Name	
Sheet	1	of	6	Attorney Docket Number	04670.105008 (SCH 2000)

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
<i>See</i>	AA	4,522,811	A	Eppstein et al.	06-11-1985	
<i>See</i>	AB	5,041,449	A	Belleau et al.	08-20-1991	
<i>See</i>	AC	5,047,407	A	Belleau et al.	09-10-1991	
<i>See</i>	AD	5,210,085	A	Liotta et al.	05-11-1993	
<i>See</i>	AE	5,539,116	A	Liotta et al.	07-23-1996	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
<i>See</i>	AF	WO	91/11186	A1	Emory University	08-08-1991		
<i>See</i>	AG	WO	92/14743	A2	Emory University	09-03-1992		
<i>See</i>	AH	WO	96/07413	A1	University of GA et al.	03-14-1996		
<i>See</i>	AI	WO	97/12033	A1	Emory University	04-03-1997		
<i>See</i>	AJ	WO	00/09531	A2	Novirio Pharm. et al.	02-24-2000		
<i>See</i>	AK	EP	0 382 526	A2	IAF BioChem Intnatl.	10-18-1989		
<i>See</i>	AL	EP	0 337 713	B1	BioChem Pharma	05-15-1996		

Examiner Signature	L. E. Crane <i>L. E. Crane</i>	Date Considered	06/19/02
--------------------	--------------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED
JUN 14 2001
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

JUN 14 2001

Application Number	09/712,481
Filing Date	November 13, 2000
First Named Inventor	Watanabe and Choi
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	04670.105008 (SCH 2000)

Sheet	2	of	6
-------	---	----	---

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
me	BA	AGUESSE-GERMON, S. et al. "Inhibitory Effect of 2'-Fluoro-5-Methyl-β-L-Arabinofuranosyl-Uracil on Duck Hepatitis B Virus Replication," <i>Antimicrob. Agents Chemother.</i> , 1998, 42 (2), 369-376. (February, 1998).	
me	BB	Alter M. J. et al. <i>J.A.M.A.</i> , 1990a, 264, 2231-2235. (November 7, 1990).	
me	BC	ALTER, M. J. et al. "The Natural History of Community-Acquired Hepatitis C in the United States," <i>N. Engl. J. Med.</i> , 1992, 327 (27), 1899-1905. (December 31, 1992).	
me	BD	Alter, M. J. <i>J. Gastro. Hepatol.</i> , 1990, 1, 78-94.	
me	BE	ALTER, H. J. et al. "Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B Hepatitis," <i>N. Engl. J. Med.</i> , 1989, 321, 1494-1500. (November 30, 1989).	
INC.	BF	<i>Antimicrob. Agents Chemother.</i>, 1986, 30, 491-498.	
me	BG	BAKER, B. R. et al. "Synthesis of Potential Anticancer Agents. VIII. Nucleosides Derived from L-Rhamnofuranose," <i>J. Org. Chem.</i> , 1957, 22, 966-971. (August, 1957).	
me	BH	BARTON, D. H. R. et al. "A New Method for the Deoxygenation of Secondary Alcohols," <i>J. Chem. Soc., Perkin Trans. I.</i> , 1975, 574-1585. (Issue No. 6).	
me	BI	CHANG, C.-N. et al. "Deoxycytidine Deaminase-resistant Stereoisomer Is the Active Form of (±)-2',3'-Dideoxy-3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication," <i>Journal of Biological Chemistry</i> , 1992, 267 (20), 13938-13942. (July 15, 1992).	
me	BJ	CHOU, T.-C. et al. "Quantitative Analysis of Dose-Effect Relationships: the Combined Effects of Multiple Drugs or Enzyme Inhibitors," <i>Adv. Enzyme Regul.</i> , 1984, 22, 27-55.	
me	BK	CHU, C. K. et al. "Use of 2'-Fluoro-5-Methyl-β-L-Arabinofuranosyluracil as a Novel Antiviral Agent for Hepatitis B Virus and Epstein-Barr Virus," <i>Antimicrob. Agents Chemother.</i> , 1995, 39 (4), 979-981. (April, 1995).	
me	BL	COOK, S. L. et al. "Nucleoside 4',5'-Enol Acetates. Synthesis and Chemistry of a Unique Uridine O ² ,4'-Anhydronucleoside," <i>J. Am. Chem. Soc.</i> , 1979, 101 (6), 1554-1564. (2/14/99).	

! Month of publication could not be determined from the copy supplied.
INC. Incomplete; see PTO-892 for complete citation.

Examiner Signature	L. E. Crane	Date Considered	06/19/02
--------------------	-------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR File [] Applicant

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)
Approved for use through 10/17/2002, GPO 1651-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

JUN 14 2001

Application Number	09/712,481
Filing Date	November 13, 2000
First Named Inventor	Watanabe and Choi
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	04670.105008 (SCH 2000)

Sheet 3 of 6

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Me	CA	DIENSTAG, J. L. "Non-A, Non-B Hepatitis. I. Recognition, Epidemiology, and Clinical Features," <i>Gastro</i> , 1983, 85, 439-462. (August, 1983).	
Me	CB !	DU, J. et al. "A Practical Synthesis of L-FMAU From L-Arabinose," <i>Nucleosides & Nucleotides</i> , 1999, 18 (2), 187-195.	
Me	CC	FOX, J. J. et al. "Pyrimidine Nucleosides. I. A New Route for the Synthesis of Thymine Nucleosides," <i>J. Am. Chem. Soc.</i> , 1956, 78, 2117-2122.M (May 20, 1956).	
Me	CD	FOX, J. J. et al. "Pyrimidine Nucleosides. IV. The Synthesis of 1-β-D-Lyxofuranosylthymine," <i>J. Am. Chem. Soc.</i> , 1958, 80, 5155-5160. (October 5, 1958).	
Me	CE !	FRIED, M. W. et al. "FIAU, A New Oral Anti-Viral Agent, Profoundly Inhibits HBV DNA in Patients with Chronic Hepatitis B," <i>AASLD Abstracts of Papers</i> , 1992, 16 (2), 127A.	
Me	CF	FURMAN, P. A. et al. "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of <i>cis</i> -5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine," <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36 (12), 2686-2692. (12/92).	
Me	CG !	HANTZ, O. et al. "Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)-5-iodocytosine and <i>E</i> -5-(2-bromovinyl)-2'-deoxyuridine," <i>Antiviral Res.</i> , 1984, 4, 187-199.	
Me	CH	HANTZ, O. et al. "Comparison of Properties of Woodchuck Hepatitis Virus and Human Hepatitis B Virus Endogenous DNA Polymerases," <i>Antimicrob. Agents Chemother.</i> , 1984, 25 (2), 242-246. (February, 1984).	
Me	CI !	HOLY, A. et al. "Nucleic Acid Components and their Analogues. CL. Preparation and Properties of Some Nucleoside Hydroxyalkanephosphonates," <i>Coll. Czech. Chem. Commun.</i> , 1972, 37, 2066-2076.	
Me	CJ !	ISHIDO, Y. et al. "Partial Protection of Carbohydrate Derivatives. Part 3. Regioselective 2'-O-Deacylation of Fully Acylated Purine and Pyrimidine Ribonucleosides with Hydrozine Hydrate," <i>J. Chem. Soc., Perkin Trans. I</i> , 1979, 2088. (Issue No. 8),	

! Month of publication could not be determined from the copy supplied.

Examiner Signature	L. E. Crane	Date Considered	06/19/02
--------------------	-------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR File [] Applicant

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/712,481
Filing Date	November 13, 2000
First Named Inventor	Watanabe and Choi
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	04670.105008 (SCH 2000)

JUN 14 2001

TECH CENTER 1600/2900

Sheet 4 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Me	DA	KAZIMIERCZUK, Z. et al. "Synthesis of 2'-Deoxytubercidin, 2'-Deoxyadenosine, and Related 2'-Deoxynucleosides via a Novel Direct Stereospecific Sodium Salt Glycosylation Procedure," <i>J. Am. Chem. Soc.</i> , 1984, 106, 6379-6382.	
Me	DB	Klecker, R. W.; Katki, A. G.; Collins, J. M.; <i>Mol. Pharmacol.</i> , 1994, 46, 1204-1209. (12/94).	
Me	DC	KORBA, B. E. et al. "A cell culture assay for compounds which inhibit hepatitis B virus replication," <i>Antiviral Res.</i> , 1991, 15, 217-228. (Issue No. 1; January, 1991).	
Me	DD	LEWIS, W. et al. "Mitochondrial toxicity of antiviral drugs," <i>Nature Medicine</i> , 1995, 1 (5), 417-422. (May, 1995).	
Me	DE ¹	LEWIS, W. et al. "Mammalian DNA Polymerases α , β , γ , δ , and ϵ Incorporate Fialuridine (FIAU) Monophosphate into DNA and Are Inhibited Competitively by FIAU Triphosphate," <i>Biochemistry</i> , 1994, 33, 14620-14624. (Issue No. 48).	
Me	DF	MACILWAIN, C. "NIH, FDA seek lessons from hepatitis B drug trial deaths," <i>Nature</i> , 1993, 364 (6435), 275. (July 22, 1993).	
Me	DG	MATSUDA, A. et al. "A Simplified Method for the Synthesis of Pyrimidine Nucleosides," <i>Synthesis</i> , 1981, 748. (Issue No. 9; September, 1981).	
Me	DH ¹	MCDUGAL, J. S. et al. "Immunoassay for the Detection and Quantitation of Infectious Human Retrovirus. Lymphadenopathy-Associated Virus (LVA)," <i>J. Immun. Meth.</i> , 1985, 76, 171-183.	
Me	DI	MCKENZIE, R. et al. "Hepatic Failure and Lactic Acidosis due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B," <i>New Eng. J. Med.</i> , 1995, 333 1099-1105. (Issue No. 17; October 26, 1995).	
Me	DJ	MIZUNO, Y. et al. "A Novel Synthesis of Purine β -D-Nucleosides via Purine 8,5'-S-Anhydronucleosides," <i>J. Am. Chem. Soc.</i> , 1972, 94 (13), 4737-4739. (06/28/72).	
Me	DK ¹	NIEDBALLA, U. et al. "A General Synthesis of N-Glycosides. I. Synthesis of Pyrimidine Nucleosides," <i>J. Org. Chem.</i> , 1974, 39 (25), 3654-3660.	

! Month of publication could not be determined from the copy supplied.

Examiner Signature	L. E. Crane	Date Considered	06/19/02
--------------------	-------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


COPY FOR ☒ File ☐ Applicant

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



RECEIVED
JUN 14 2001
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/712,481
Filing Date	November 13, 2000
First Named Inventor	Watanabe and Choi
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	04670.105008 (SCH 2000)

Sheet 5 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Me	EA	PAI, S. P. et al. "Inhibition of Hepatitis B Virus by a Novel L-Nucleoside, 2'-Fluoro-5-Methyl-β-L-Arabinofuranosyl Uracil," <i>Antimicrob. Agents. Chemother.</i> , 1996, 40 (2), 380-386. (February, 1996).	
Me	EB	PANKIEWICZ, K. et al. "Nucleosides. 121. Improved and General Synthesis of 2'-Deoxy-C-Nucleosides. Synthesis of 5-(2-Deoxy-β-D-erythro-pentofuranosyl)uracil, -1-methyluracil, -1,3-dimethyluracil, and -isouracil," <i>J. Org. Chem.</i> , 1982, 47 (3), 485. (Jan. 29, 1982).	
Me	EC	PARKER, W. B. et al. "Mitochondrial Toxicity of Antiviral Nucleoside Analogs," <i>J. NIH Res.</i> , 1994, 6, 57-61. (March, 1994).	
Me	ED	PFITZNER, K. E. et al. "Sulfoxide-Carbodiimide Reactions. I. A Facile Oxidation of Alcohols," <i>J. Am. Chem. Soc.</i> , 1965, 87 (24), 5661-5670. (December 20, 1965).	
Me	EE ¹	RAAD, I. et al. "Maximal Sterile Barriers (MSB) During the Insertion of Central Venous Catheters (CVC) for the Prevention of Infections: A Prospective Randomized Study," Abstracts of the 32 nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992, Abstract #264	
Me	EF	REIST, E. J. et al. "Synthesis of 9-β-D-Arabinofuranosylguanine," <i>Biochemistry</i> , 1964, 3 (1), 15-18. (January, 1964).	
Me	EG	ROBINS, M. J. et al. "Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereospecific Conversion of Ribonucleosides to 2'-Deoxynucleosides," <i>J. Am. Chem. Soc.</i> , 1983, 105 (12), 4059-4065. (June 15, 1983).	
Me	EH	SCHINAZI, R. F. et al. "Activities of 3'-Azido-3'-Deoxythymidine Nucleotide Dimers in Primary Lymphocytes Infected with Human Immunodeficiency Virus Type 1," <i>Antimicrob. Agents Chemother.</i> , 1990, 34 (6), 1061. (June, 1990).	
Me	EI	SCHINAZI, R. F. et al. "Combinations of Isoprinosine and 3'-Azido-3'-Deoxythymidine in Lymphocytes Infected with Human Immunodeficiency Virus Type 1," <i>Antimicrob. Agents Chemother.</i> , 1988, 32 (12), 1784-1787. (December, 1988).	

¹ Month of publication could not be determined from the copy supplied.

Examiner Signature	L. E. Crane <i>LE Crane</i>	Date Considered	06/19/02
--------------------	-----------------------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR ☒ File ☐ Applicant

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)
Approved for use through 10/31/2002 (OMB #0703-0188)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known JUN 14 2001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/712,481
				Filing Date	November 18, 2000
				First Named Inventor	Watanabe and Choi
				Group Art Unit	1623
				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	04670.105008 (SCH 2000)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
Me	FA	SCHINAZI, R. F. et al. "Effect of Combinations of Acyclovir with Vidarabine or Its Monophosphate on Herpes Simplex Viruses in Cell Culture and in Mice," <i>Antimicrobial Agents and Chemotherapy</i> , 1982, 22 (3), 499-507. (September, 1982).		
Me	FB	SCHINAZI, R. F. et al. "Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl]Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36 (11), 2423-2431. (11/92).		
Me	FC	SMEJKAL, J. et al. "Nucleic Acids Components and their Analogues. LII. Preparation of 1,2'-Deoxy-β-L-Ribofuranoxylthymine, 'L-Thymidine'," <i>Coll. Czech. Chem. Commun.</i> , 1964, 29 (11), 2809-2813. (November, 1964).		
Me	FD	SPIRA, T. J. et al. "Micromethod for Assaying Reverse Transcriptase of Human T-Cell Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus," <i>J. Clin. Meth.</i> , 1987, 25, 97-99. (Issue No. 1; January, 1987).		
Me	FE !	TENNANT, B. et al. "Pharmacokinetic and Pharmacodynamic Studies of 1-(2-Fluoro-5-methyl-β-L-arabinofuranosyl)uracil (L-FMAU) in the Woodchuck Model of Hepatitis B Virus (HBV) Infection," <i>Antiviral Res.</i> , 1996, 34 (2), A52.		
Me	FF	TOUCHETTE, N. "HBV-Drug Deaths Prompt Restudy of Similar Antivirals," <i>J. NIH Res.</i> , 1993, 5, 33-35. (September, 1993).		
Me	FG !	VORBRUGGEN, H. et al. "Nucleoside Synthesis with Trimethylsilyl Triflate and Perchlorate as Catalysts," <i>Chem. Ber.</i> , 1981, 114, 1234-1255.		
Me	FH	WATANABE, K. A. et al. "Nucleosides LVII. A Simplified Method for the Synthesis of Pyrimidine Nucleosides (1,2)," <i>J. Heterocycl. Chem.</i> , 1969, 6, 109-110. (February, 1969).		
Me	FI	Yamaguchi, T. et al. "Synthetic Nucleosides and Nucleotides. XXI. On the Synthesis and Biological Evaluations of 2'-Deoxy-α-D-ribofuranosyl Nucleosides and Nucleotides," <i>Chem. Pharm. Bull.</i> , 1984, 32 (4), 1441-1450. (April, 1984).		

! Month of publication data could not be determined from the copy supplied.


Examiner Signature	L. E. Crane	Date Considered	06/19/02
--------------------	-------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR ☒ File ☐ Applicant



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/712,481
Filing Date	November 13, 2000
First Named Inventor	Watanabe <i>et al.</i>
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	08841.105008 PHA 1010

**COPY OF PAPERS
ORIGINALLY FILED**

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

L. E. Crane

06/15/02

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for ~~for~~ ^{the} A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known


Application Number	09/712,481
Filing Date	November 13, 2000
First Named Inventor	Watanabe <i>et al.</i>
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	08841.105008 PHA 1010

Sheet	2	of	2
-------	---	----	---

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

! Month of publication data could not be determined from the copy supplied.

Examiner Signature	L. E. Crane		Date Considered	06/15/02
--------------------	-------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.